Analysis The Relationship Between Survivin And Bcl-2Expression And The Therapeutic Efficacy In Multiple Myeloma

Clinical stage reflect the disease phase and tumor burden.in multiple myeloma (MM). Durie-Salmon (DS) and International Staging System (ISS) stratification are two widely accepted staging system presently, which are both divided into three different stages according to the clinical and laboratory data and provide the prognostic informations. Recently, Mayo clinic stratified the newly diagnosed myeloma into standard, intermediate-and high risk-disease useing fluorescent in situ hybridization studies and conventional karyotyping, which provide the cytogenetic markers and the risk-adapted therapy classification. However, analysising the datas of the newly diagnosed MM admitted to our department during the last year, we found out that we still have a long way to achieve the Mayo stratification usage routinely; the outcomes of the MM patients in the same stage according the DS/ISS system whcih accepted the same chemotherapies were different. So novel molecular markers might offer potential information for treatments in MM. We measured the expression of Survivin and Bcl-2in the newly diagnosed MM last year in our hospital by inmmunohistochemistry and analysis the correlation between expression and the chemotherapeutic efficacy. The results showed that regardless the expression level of Survivin and Bcl-2, bortezomib could effectively decrease the tumor burden and achieve response. The non-bortezomib agents were effective in the absent of Survivn and Bcl-2expression. However, once Survivin and Bcl-2were single or double positive, the newly diagnosed MM patients had no response for non-bortezomib agents. According this study, we recommend the newly diagnosed MM whcih were Survivin and Bcl-2single or double positive by inmmunohistochemistry received the bortezomib for anti-myeloma therapy.